CDER lists guidances in the works for 2009
This article was originally published in The Gold Sheet
FDA's Center for Drug Evaluation and Research has listed several drug quality-related documents on its guidance agenda for 2009, including ones in the chemistry category for: CMC postmarketing plans, annually reportable CMC post-approval changes, assay development for immunogenicity testing, immunogenicity assessment for therapeutic protein products, incorporation of physical-chemical identifiers into solid oral dosage forms for anti-counterfeiting, and standards recognition. In the compliance category, CDER is developing guidances on contract manufacturing, dosage delivery devices for OTC liquids, non-penicillin beta-lactam contamination, Part 11 electronic records, positron emission tomography cGMPs, pharmaceutical component quality control, pharmaceutical components at risk for melamine contamination, pharmaceutical manufacturing statistics, pre-launch activities importation request, and process validation general principles and practices
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.